DD, I'm of the same opinion as you regarding Dr Malkin, but since he is a MD, I give him the respect of listening to what he had to say. Here's my rebuttal:
1) It is one of the most striking coincidences I've ever seen that every MD critic of DCVax-L has ties to NVCR.
2) Much of what Dr. Malkin said in the Musella interview is simply not true. NWBO did not violate protocol and they did everything in accordance with FDA standards. This might not be obvious for some folks... I encourage everyone to do their own due diligence and get read the rebuttals out there from doctors who were involved in the trial. Also, do you really think JAMA did not due their own diligence on that when they published the article?
3) Dr. Malkin says he's "very very very" familiar with the DCV-L trial. Ok, Dr... you didn't participate in the trial itself... so where are you getting your information from? Obviously not from the 77 doctors in the JAMA article who believe in what they've accomplished. When you look at his financial disclosures there's a lot of paid sales/consultant dinners from NVCR. Clearly the DCV-L trial is being discussed in NVCR circles and sales dinners. Clearly they see it as a threat and one of the reasons their market cap has gone down the toilet. I've personally attended sales dinners like this (in a different industry) and the rhetoric he's quoting are the sort of lies they'll spin at these dinners to undermine the competition. It's ugly, but that's the reality of business. Clearly, there are many important doctors that believe in what's going on here.
4) Look at the grimace on Dr Malkin's face after he bashes the DCV-L trial! I've seen that look before, and it's the look of a man who's questioning what he just said... who's overcome with guilt and not confident he's doing the right thing.
The rubber meets the road at the MHRA. We will see what the oncology community decides to move forward with.
For the record, I think NWBO would get an FDA approval even if that was their first regulatory submission, but this is why NWBO is going with MHRA first. Fewer decision makers at the MHRA have NVCR's fangs in them.
Market Data 
Markets 
AI
